Title: The Therapeutic Potential of Cannabidiol (CBD) Oil & ™ Zeolite Z™ in an aqueous colloidal solution of SOLergy™ Sea Minerals™ in the Prevention and Treatment of Any Cancerou s Condition and Other Health Conditions
Cannabidiol, CBD oil, cancer Treatment, multiple myeloma, MasterPeace™ Zeolite Z™, SOLergy™, sea minerals, detoxification, therapeutic benefits, cannabinoids, colloidal, colloids
Cannabidiol (CBD) is one of over a hundred active compounds found in the cannabis plant, known for its non-psychoactive properties and potential therapeutic effects. Unlike tetrahydrocannabinol (T.H.C.), which is primarily responsible for the &quot;high&quot; associated with marijuana, CBD has gained popularity for its wide-ranging health benefits[^1^].
In recent years, there has been an increasing interest in the use of CBD oil for various medical conditions, including chronic pain, anxiety disorders, epilepsy, and particularly in the realm of oncology[^2^].
CBD has gained attention for its effectiveness in treating certain types of epilepsy, particularly in children. The F.D.A. has approved Epidiolex, a CBD-based medication, for the Treatment of Dravet syndrome and Lennox-Gastaut syndrome[^14^].
[14] Devinsky, O. et al. (2017). “Cannabidiol in Patients with Treatment-Resistant Epilepsy: An Open-Label Interventional Trial”; The Lancet Neurology, 16(3), 281-290. Link
Multiple Myeloma: A study by Nabissi et al. (2016) demonstrated that cannabinoids, specifically CBD and T.H.C., synergize with carfilzomib (a proteasome inhibitor), reducing the Viability and migration of multiple myeloma cells. The combination of CBD and T.H.C. was shown to induce autophagic-dependent necrosis, significantly decreasing cell viability in
multiple myeloma cell lines (U266 and RPMI) through a 4:1 CBD to THC ratio[^15^].
Two studies further support these findings, showing that the combination of CBD and T.H.C. exhibits vigorous anti-multiple myeloma activity, enhancing cytotoxic effects and impeding tumor progression[^16^][^17^].
Other Cancers: CBD with T.H.C. has been found to act synergistically with other chemotherapeutic agents, enhancing their anti-tumor effects. For instance, in glioblastoma (G.B.M.), CBD and the THC-CBD combination effectively reduced cell viability and induced apoptosis in vitro and xenograft models[^18^].
5. Detoxification with MasterPeace™ Zeolite Z™ in an aqueous colloidal solution of SOLergy™ Sea Minerals™:
Incorporating MasterPeace™ Zeolite Z™ in an aqueous colloidal solution of SOLergy™ Sea Minerals™ may enhance the detoxification process in cancer Treatment. This natural Isupplement is designed to help remove known carcinogens called “forever chemicals” such as P.F.O.S. and P.F.O.A., as well as nanometals (graphene, aluminum, titanium, and ferric oxides), microplastics, heavy metals (lead and mercury), and radioactive metals (plutonium, cadmium, cesium-136). By removing these harmful carcinogentic substances, MasterPeace™ Zeolite Z™ in an aqueous colloidal solution of SOLergy™ Sea Minerals™ may support overall health and improve the efficacy of CBD and T.H.C. in any cancerous Treatment[^6^].
Some studies suggest that CBD may improve sleep quality and help with insomnia, potentially by addressing underlying issues such as anxiety or pain[^19^].
7. Anti-Inflammatory Properties:
CBD’s anti-inflammatory effects may benefit inflammatory bowel disease (IBD), autoimmune diseases, and other inflammatory conditions[^20^].
In glioblastoma (G.B.M.), both CBD and the THC-CBD combination have been found to reduce cell viability and induce apoptosis in vitro and G.B.M. xenograft models[^24^].
Additionally, CBD induces apoptotic cell death in lung cancer cell lines (A549 and H460) and shows tumor regression in A549-xenografted nude mice[^25^].
In breast cancer, T.H.C. inhibits cell proliferation by blocking the cell cycle and inducing apoptotic cell death[^26^], while CBD inhibits A.K.T. and mTOR signaling, promoting autophagic cell death[^27^]. Previous findings in multiple myeloma have demonstrated that CBD reduces cell proliferation and induces necrotic cell death[^28^].
The current data support the role of T.H.C. and the THC-CBD combination as stimulatory factors of autophagic-dependent cell death in multiple myeloma cell lines, reinforcing the efficacy of cannabinoids as anti-tumoral drugs in various human cancer models[^29^].
Combining cannabinoids with established chemotherapy agents enhances their anti-tumor activity. In G.B.M., combining temozolomide and carmustine with CBD or THC-CBD synergistically increases G.B.M. cell death both in vitro and in vivo. Furthermore, CBD has been shown to enhance doxorubicin uptake in triple-negative breast cancer cells, significantly improving its anti-tumor efficacy[^30^][^31^].
In multiple myeloma, the combination of CBD and bortezomib (B.T.Z.) was found to be more effective in inducing cell death than B.T.Z[^32^] when administered alone. C.B.D. and B.T.Z. act synergistically to induce cell death.[^33^]
The investigation of CBD and T.H.C., in combination with C.F.Z., reveals a synergistic effect among the three drugs, supporting the notion that combining THC-CBD with established cytotoxic agents may yield a higher level of anticancer activity compared to cytotoxic agents acting alone[^33^].
Moreover, removing heavy metals, forever chemicals, microplastics, nanotechnology of graphene, and radioactive metals through detoxification methods, such as MasterPeace™ Zeolite Z™ in an aqueous colloidal solution of SOLergy™ Sea Minerals™, can significantly prevent and treat cancerous conditions. By eliminating these harmful substances from the body, the burden on the immune system can be reduced, potentially enhancing the effectiveness of cancer therapies and improving overall health outcomes.[^6^]
Current studies highlight the importance of detoxification in cancer management, suggesting that a comprehensive approach that includes both cannabinoid therapy and detoxification strategies may yield synergistic benefits in any cancer Treatment[^34^].
While CBD oil is generally considered safe for most people, it can cause side effects in some individuals. Common side effects of CBD include[^35^]:
Fatigue: Some users may experience drowsiness or fatigue.
Fatigue: Some users may experience drowsiness or fatigue.
Diarrhea: Gastrointestinal issues, including diarrhea, can occur.
Diarrhea: Gastrointestinal issues, including diarrhea, can occur.
Changes in Appetite or Weight: CBD may affect appetite, leading to weight gain or loss.
Changes in Appetite or Weight: CBD may affect appetite, leading to weight gain or loss.
Dry Mouth: Some individuals report experiencing dry mouth after using CBD[^35^].
Dry Mouth: Some individuals report experiencing dry mouth after using CBD[^35^].
T.H.C. can also produce side effects, which may include[^36^]:
Psychoactive Effects: Unlike CBD, T.H.C. is psychoactive and can cause a “high,” which may lead to anxiety or paranoia in some users.
Psychoactive Effects: Unlike CBD, T.H.C. is psychoactive and can cause a “high,” which may lead to anxiety or paranoia in some users.
Increased Heart Rate: T.H.C. can cause tachycardia (increased heart rate), which may concern individuals with certain cardiovascular conditions.
Increased Heart Rate: T.H.C. can cause tachycardia (increased heart rate), which may concern individuals with certain cardiovascular conditions.
Impaired Coordination: T.H.C. can affect motor skills and coordination, making activities like driving dangerous.
Impaired Coordination: T.H.C. can affect motor skills and coordination, making activities like driving dangerous.
Short-Term Memory Impairment: T.H.C. may temporarily impair short-term memory and cognitive functions.
Short-Term Memory Impairment: T.H.C. may temporarily impair short-term memory and cognitive functions.
It is essential to consult a healthcare provider before starting CBD oil, T.H.C., or MasterPeace™ Zeolite Z™ in an aqueous colloidal solution of SOLergy™ Sea Minerals™, especially for individuals taking other medications or with pre-existing health conditions. Monitoring for unusual symptoms or side effects is crucial for ensuring safety during any cancer Treatment.
Martínez, V., Iriondo De-Hond, A., Borrelli, F., Capasso, R., Del Castillo, M. D., & Abalo, R. (2020). Cannabidiol and other non-psychoactive cannabinoids for preventing and treating gastrointestinal disorders: beneficial nutraceuticals? International Journal of Molecular Sciences , 21 (9), 3067. Vučković, S., et al. (2018). “Cannabinoids and Pain: New Insights from Old Molecules.” Frontiers in Pharmacology, 9, 1259. Link
Martínez, V., Iriondo De-Hond, A., Borrelli, F., Capasso, R., Del Castillo, M. D., & Abalo, R. (2020). Cannabidiol and other non-psychoactive cannabinoids for preventing and treating gastrointestinal disorders: beneficial nutraceuticals? International Journal of Molecular Sciences , 21 (9), 3067. Vučković, S., et al. (2018). “Cannabinoids and Pain: New Insights from Old Molecules.” Frontiers in Pharmacology, 9, 1259. Link
Fiani, B., Sarhadi, K. J., Soula, M., Zafar, A., & Quadri, S. A. (2020). Current application of cannabidiol (CBD) in the management and Treatment of neurological disorders. Neurological Sciences , 41 , 3085-3098.
Fiani, B., Sarhadi, K. J., Soula, M., Zafar, A., & Quadri, S. A. (2020). Current application of cannabidiol (CBD) in the management and Treatment of neurological disorders. Neurological Sciences , 41 , 3085-3098.
Mahler, G. (2022). Cannabidiol and other phytocannabinoids as cancer therapeutics. Pharmaceutical Medicine , 36 (2), 99–129.
Mahler, G. (2022). Cannabidiol and other phytocannabinoids as cancer therapeutics. Pharmaceutical Medicine , 36 (2), 99–129.
Dariš, B., Verboten, M. T., Knez, Ž., & Ferk, P. (2019). Cannabinoids in cancer Treatment: Therapeutic potential and legislation. Bosnian journal of basic medical sciences , 19 (1), 14.
Dariš, B., Verboten, M. T., Knez, Ž., & Ferk, P. (2019). Cannabinoids in cancer Treatment: Therapeutic potential and legislation. Bosnian journal of basic medical sciences , 19 (1), 14.
Afrin, F., Chi, M., Eamens, A. L., Duchatel, R. J., Douglas, A. M., Schneider, J., … & Dun, M. D. (2020). Can hemp help? Low-THC cannabis and non-THC cannabinoids for the Treatment of Cancer. Cancers , 12 (4), 1033.
Afrin, F., Chi, M., Eamens, A. L., Duchatel, R. J., Douglas, A. M., Schneider, J., … & Dun, M. D. (2020). Can hemp help? Low-THC cannabis and non-THC cannabinoids for the Treatment of Cancer. Cancers , 12 (4), 1033.
Young, R. O., & Mansfield, C. A. (2024). “MasterPeace™ Zeolite Z™ Pilot StudyFound to be Safe and Effective in Removing Nano and Micro Toxic Forever Chemicals, Heavy Metals, Micro Plastics and Graphene and Aluminum Found in the Human Body Cells and Fluids.&quot; Acta Scientific Medical Sciences, 8(9), 111-117.
Young, R. O., & Mansfield, C. A. (2024). “MasterPeace™ Zeolite Z™ Pilot StudyFound to be Safe and Effective in Removing Nano and Micro Toxic Forever Chemicals, Heavy Metals, Micro Plastics and Graphene and Aluminum Found in the Human Body Cells and Fluids.&quot; Acta Scientific Medical Sciences, 8(9), 111-117.
Nelson, K. M., Bisson, J., Singh, G., Graham, J. G., Chen, S. N., Friesen, J. B., … & Pauli, G. F. (2020). The essential medicinal chemistry of cannabidiol (CBD). Journal of medicinal chemistry , 63 (21), 12137-12155.
Nelson, K. M., Bisson, J., Singh, G., Graham, J. G., Chen, S. N., Friesen, J. B., … & Pauli, G. F. (2020). The essential medicinal chemistry of cannabidiol (CBD). Journal of medicinal chemistry , 63 (21), 12137-12155.
Nelson, K. M., Bisson, J., Singh, G., Graham, J. G., Chen, S. N., Friesen, J. B., … & Pauli, G. F. (2020). The essential medicinal chemistry of cannabidiol (CBD). Journal of medicinal chemistry , 63 (21), 12137-12155.
Nelson, K. M., Bisson, J., Singh, G., Graham, J. G., Chen, S. N., Friesen, J. B., … & Pauli, G. F. (2020). The essential medicinal chemistry of cannabidiol (CBD). Journal of medicinal chemistry , 63 (21), 12137-12155.
Casajuana Kögel, C., López-Pelayo, H., Balcells-Olivero, M. M., Colom, J., & Gual, A. (2018). Psychoactive constituents of cannabis and their clinical implications: a systematic review. Adicciones , 30 (2).
Casajuana Kögel, C., López-Pelayo, H., Balcells-Olivero, M. M., Colom, J., & Gual, A. (2018). Psychoactive constituents of cannabis and their clinical implications: a systematic review. Adicciones , 30 (2).
Rupasinghe, H. V., Davis, A., Kumar, S. K., Murray, B., & Zheljazkov, V. D. (2020). Industrial hemp (Cannabis sativa subsp. sativa) is an emerging source of value-added functional food ingredients and nutraceuticals. Molecules , 25 (18), 4078.
Rupasinghe, H. V., Davis, A., Kumar, S. K., Murray, B., & Zheljazkov, V. D. (2020). Industrial hemp (Cannabis sativa subsp. sativa) is an emerging source of value-added functional food ingredients and nutraceuticals. Molecules , 25 (18), 4078.
Häuser, W., Petzke, F., & Fitzcharles, M. A. (2018). Efficacy, tolerability, and safety of cannabis‐based medicines for chronic pain management–An overview of systematic reviews. European Journal of Pain , 22 (3), 455-470.
Häuser, W., Petzke, F., & Fitzcharles, M. A. (2018). Efficacy, tolerability, and safety of cannabis‐based medicines for chronic pain management–An overview of systematic reviews. European Journal of Pain , 22 (3), 455-470.
CBD may interact with brain and immune system receptors to reduce inflammation and alleviate pain
CBD may interact with brain and immune system receptors to reduce inflammation and alleviate pain
Blessing, E. M., et al. (2015). “Cannabidiol as a Potential Treatment for Anxiety Disorders.” Neurotherapeutics , 12 (4), 825–836. Link
Blessing, E. M., et al. (2015). “Cannabidiol as a Potential Treatment for Anxiety Disorders.” Neurotherapeutics , 12 (4), 825–836. Link
Devinsky, O. et al. (2017). “Cannabidiol in Patients with Treatment-Resistant Epilepsy: An Open-Label Interventional Trial.” The Lancet Neurology , 16 (3), 281–290. Link
Devinsky, O. et al. (2017). “Cannabidiol in Patients with Treatment-Resistant Epilepsy: An Open-Label Interventional Trial.” The Lancet Neurology , 16 (3), 281–290. Link
Nabissi, M., et al. (2016). “Cannabinoids Synergize with Carfilzomib, Reducing Multiple Myeloma Cells Viability and Migration.” Journal of Cellular Physiology. [Linkto study if available]
Nabissi, M., et al. (2016). “Cannabinoids Synergize with Carfilzomib, Reducing Multiple Myeloma Cells Viability and Migration.” Journal of Cellular Physiology. [Linkto study if available]
Marcu, J.P., Christian, R.T., Lau, D., Zielinski, A.J., Horowitz, M.P., Lee, J., Pakdel, A., Allison, J., Limbad, C., Moore, D.H., Yount, G.L., Desprez, P.Y., McAllister, S.D. (2010). “Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival. Molecular Cancer Therapeutics.” 9(1), 180-189.
Marcu, J.P., Christian, R.T., Lau, D., Zielinski, A.J., Horowitz, M.P., Lee, J., Pakdel, A., Allison, J., Limbad, C., Moore, D.H., Yount, G.L., Desprez, P.Y., McAllister, S.D. (2010). “Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival. Molecular Cancer Therapeutics.” 9(1), 180-189.
7. Babson, K. A., et al. (2017). “Cannabinoids and Sleep: A Review of the Literature.” Current Psychiatry Reports, 19(4), 23. Link
7. Babson, K. A., et al. (2017). “Cannabinoids and Sleep: A Review of the Literature.” Current Psychiatry Reports, 19(4), 23. Link
Van De Velde, F., et al. (2016). “The Role of Cannabinoids in the Treatment of Inflammatory Bowel Disease.” Journal of Clinical Gastroenterology, 50(5), 418-426. Link
Van De Velde, F., et al. (2016). “The Role of Cannabinoids in the Treatment of Inflammatory Bowel Disease.” Journal of Clinical Gastroenterology, 50(5), 418-426. Link
Hasan, N., Imran, M., Sheikh, A., Saad, S., Chaudhary, G., Jain, G. K., … Ahmad, F. J. (2022). Cannabis is a potential compound against various malignancies, legal aspects, and advancement by exploiting nanotechnology and clinical trials. Journal of Drug Targeting , 30 (7), 709–725. https://doi.org/10.1080/1061186X.2022.2056188 . Link
Hasan, N., Imran, M., Sheikh, A., Saad, S., Chaudhary, G., Jain, G. K., … Ahmad, F. J. (2022). Cannabis is a potential compound against various malignancies, legal aspects, and advancement by exploiting nanotechnology and clinical trials. Journal of Drug Targeting , 30 (7), 709–725. https://doi.org/10.1080/1061186X.2022.2056188 . Link
Liberati, S. (2014). The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2.
Liberati, S. (2014). The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2.
Maina, S., Misinzo, G., Bakari, G., & Kim, H. Y. (2020). A systematic review of human, animal, and plant health benefits of glucosinolates and strategies for enhanced bioactivity. Molecules , 25 (16), 3682.
Maina, S., Misinzo, G., Bakari, G., & Kim, H. Y. (2020). A systematic review of human, animal, and plant health benefits of glucosinolates and strategies for enhanced bioactivity. Molecules , 25 (16), 3682.
Nabissi, M., Morelli, M.B., Santoni, M., & Santoni, G. (2016). “Triggering the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents.” Carcinogenesis , 34(1), 48–57.
Nabissi, M., Morelli, M.B., Santoni, M., & Santoni, G. (2016). “Triggering the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents.” Carcinogenesis , 34(1), 48–57.
Torres, S., Lorente, M., Rodríguez-Fornés, F., Hernández-Tiedra, S., Salazar, M., García-Taboada, E., … & Velasco, G. (2011). A combined preclinical therapy of cannabinoids and temozolomide against glioma. Molecular cancer therapeutics , 10 (1), 90-103.
Torres, S., Lorente, M., Rodríguez-Fornés, F., Hernández-Tiedra, S., Salazar, M., García-Taboada, E., … & Velasco, G. (2011). A combined preclinical therapy of cannabinoids and temozolomide against glioma. Molecular cancer therapeutics , 10 (1), 90-103.
Ramer, R., & Hinz, B. (2016). Antitumorigenic targets of cannabinoids–current status and implications. Expert opinion on therapeutic targets , 20 (10), 1219-1235.
Ramer, R., & Hinz, B. (2016). Antitumorigenic targets of cannabinoids–current status and implications. Expert opinion on therapeutic targets , 20 (10), 1219-1235.
Lin, B., Gao, Y., Li, Z., Zhang, Z., Lin, X., & Gao, J. (2020). Cannabidiol alleviates hemorrhagic shock‐induced neural apoptosis in rats by inducing autophagy by activating the PI3K/AKT pathway. Fundamental & Clinical Pharmacology , 34 (6), 640–649.
Lin, B., Gao, Y., Li, Z., Zhang, Z., Lin, X., & Gao, J. (2020). Cannabidiol alleviates hemorrhagic shock‐induced neural apoptosis in rats by inducing autophagy by activating the PI3K/AKT pathway. Fundamental & Clinical Pharmacology , 34 (6), 640–649.
Morelli, M. B., Offidani, M., Alesiani, F., Discepoli, G., Liberati, S., Olivieri, A., … & Nabissi, M. (2014). The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type‐2. International journal of cancer , 134 (11), 2534-2546.
Morelli, M. B., Offidani, M., Alesiani, F., Discepoli, G., Liberati, S., Olivieri, A., … & Nabissi, M. (2014). The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type‐2. International journal of cancer , 134 (11), 2534-2546.
Hinz, B., & Ramer, R. (2019). Anti‐tumour actions of cannabinoids. British journal of pharmacology , 176 (10), 1384-1394.
Hinz, B., & Ramer, R. (2019). Anti‐tumour actions of cannabinoids. British journal of pharmacology , 176 (10), 1384-1394.
Torres, S., Lorente, M., Rodríguez-Fornés, F., Hernández-Tiedra, S., Salazar, M., García-Taboada, E., … & Velasco, G. (2011). A combined preclinical therapy of cannabinoids and temozolomide against glioma. Molecular cancer therapeutics , 10 (1), 90-103.
Torres, S., Lorente, M., Rodríguez-Fornés, F., Hernández-Tiedra, S., Salazar, M., García-Taboada, E., … & Velasco, G. (2011). A combined preclinical therapy of cannabinoids and temozolomide against glioma. Molecular cancer therapeutics , 10 (1), 90-103.
Hinz, B., & Ramer, R. (2019). Anti‐tumour actions of cannabinoids. British journal of pharmacology , 176 (10), 1384-1394.
Hinz, B., & Ramer, R. (2019). Anti‐tumour actions of cannabinoids. British journal of pharmacology , 176 (10), 1384-1394.
Tatekawa, S., Chinen, Y., Ri, M., Narita, T., Shimura, Y., Matsumura‐Kimoto, Y., … & Kuroda, J. (2017). Epigenetic repression of miR‐375 is the dominant mechanism for constitutive activation of the P.D.P.K. 1/RPS 6 K.A. 3 signaling axis in multiple myeloma. British Journal of Haematology , 178 (4), 534-546.
Tatekawa, S., Chinen, Y., Ri, M., Narita, T., Shimura, Y., Matsumura‐Kimoto, Y., … & Kuroda, J. (2017). Epigenetic repression of miR‐375 is the dominant mechanism for constitutive activation of the P.D.P.K. 1/RPS 6 K.A. 3 signaling axis in multiple myeloma. British Journal of Haematology , 178 (4), 534-546.
Opitz, B. J., Ostroff, M. L., & Whitman, A. C. (2020). The potential clinical implications and importance of drug interactions between anticancer agents and cannabidiol in patients with cancer. Journal of Pharmacy Practice , 33 (4), 506-512.
Opitz, B. J., Ostroff, M. L., & Whitman, A. C. (2020). The potential clinical implications and importance of drug interactions between anticancer agents and cannabidiol in patients with cancer. Journal of Pharmacy Practice , 33 (4), 506-512.
Louis, B. W. S. (Ed.). (2018). Cannabis: a clinician’s guide . C.R.C. Press.
Louis, B. W. S. (Ed.). (2018). Cannabis: a clinician’s guide . C.R.C. Press.
Machado Rocha, F. C., Stéfano, S. C., De Cassia Haiek, R., Rosa Oliveira, L. M. Q., & Da Silveira, D. X. (2008). Therapeutic use of Cannabis sativa on chemotherapy‐induced nausea and vomiting among cancer patients: systematic review and meta‐analysis. European journal of cancer care , 17 (5), 431-443.
Machado Rocha, F. C., Stéfano, S. C., De Cassia Haiek, R., Rosa Oliveira, L. M. Q., & Da Silveira, D. X. (2008). Therapeutic use of Cannabis sativa on chemotherapy‐induced nausea and vomiting among cancer patients: systematic review and meta‐analysis. European journal of cancer care , 17 (5), 431-443.